Parabilis to Present Zolucatetide Trial Data in Madrid
The company will share phase 1/2 results on October 24, 2026, at the European Society for Medical Oncology Congress.
Updated on Oct. 19, 2026 in Cancer
Parabilis Medicines is set to present findings from its phase 1/2 zolucatetide clinical trial on October 24, 2026. The presentation will cover data from dose-escalation and dose-optimization stages regarding the treatment of desmoid tumors.
Why it matters
The findings are intended to inform the selection of a specific dose and schedule for a future phase 3 trial. This research aims to address connective-tissue growths by disrupting the interaction between beta-catenin and T-cell factor.
The clinical data encompasses results collected through a cutoff date of June 22, 2026. The study focuses on zolucatetide, an investigational drug designed to inhibit the binding of beta-catenin and T-cell factor.
The players
Parabilis Medicines
This biotechnology firm specializes in developing investigational drugs that target complex molecular interactions.
European Society for Medical Oncology
This is a professional organization for medical oncology that hosts international congresses to share clinical research developments.
The details
The company will share these results during a sarcoma session at the European Society for Medical Oncology Congress in Madrid. Following the presentation, Parabilis Medicines will host an investor webcast to further discuss the trial data.
Timeline
June 22, 2026, was the clinical trial data cutoff date.
October 24, 2026, is the date of the European Society for Medical Oncology Congress presentation.
The sarcoma session presentation is scheduled for 8:45 a.m. to 10:15 a.m. ET.
The investor webcast is scheduled for noon ET.
The Big Picture
This presentation follows a standard pattern set by the European Society for Medical Oncology Congress for unveiling critical oncology advancements. The data release marks a pivot point as the company moves from early-stage testing toward a pivotal late-stage study.
The potential initiation of a phase 3 trial for desmoid tumors could eventually broaden treatment options for patients with these connective-tissue growths. Currently, the research remains in the investigational stage and does not impact immediate clinical care or treatment protocols.
The takeaway
Zolucatetide represents a targeted approach to managing desmoid tumors by focusing on specific protein-factor interactions. Future updates regarding the planned phase 3 trial will be essential for determining the long-term feasibility of this treatment pathway.
Further reading
For more on the evolving landscape of oncological research, visit the Cancer section.
Source note: This article includes information reported by TokenPost.
